At least 206 million people are estimated to have required treatment for schistosomiasis in 2016. While the actual reported number of people treated in 2016 was 89.2 million.
People become infected when larval forms of the parasite – released by freshwater snails – penetrate the skin during contact with infested water.
Schistosomiasis is especially prevalent in poor communities with unsafe drinking-water sources and inadequate sanitation. It is estimated that at least 90% of those requiring treatment for schistosomiasis live in Africa.
Increased migration to urban areas and population movements are introducing schistosomiasis to new areas. Increasing population size and the corresponding needs for power and water often result in development schemes and environmental modification, such as construction of dams, that facilitate transmission.
In children, schistosomiasis causes anaemia, stunted growth and reduced ability to learn, although its effects are usually reversible with treatment. Chronic schistosomiasis can affect people’s ability to work and, in some cases, result in death. Female genital schistosomiasis (FGS) symptoms of vaginal discharge, bleeding, and pain during sexual intercourse can also lead to infertility.
Urogenital schistosomiasis can be easily detected through the presence of blood in urine (haematuria). Intestinal forms of schistosomiasis can cause abdominal pain, diarrhoea and blood in the stool, are diagnosed through examination of stool specimens.
Control of schistosomiasis is based on large-scale treatment with praziquantel of at-risk populations. WHO recommends treatment with praziquantel against all forms of schistosomiasis. The medicine is effective, safe and is distributed free during large-scale treatment campaigns.
WHO has also developed methods and recommendations to reach communities and simplify large-scale preventive treatment with praziquantel. Other methods of schistosomiasis control include improved sanitation, clean water supply, health education and snail control.
WHO has catalysed collaboration between ministries of health, development agencies, the pharmaceutical sector, non-profit organizations and communities to provide resources and medicines for schistosomiasis control.